Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2024-02-28 Interim / Quarterly Rep…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
MSB Q2 Financial Results and Operational Highlights 8 pages 637.8KB
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial and operational update for the half-year ended December 31, 2023, including comprehensive financial results, operational highlights, regulatory updates, and clinical trial progress. It contains substantive financial data such as cash usage, expenses, royalties, and net loss figures for the six-month period, as well as detailed discussion of business activities and regulatory interactions. The presence of actual financial statements and analysis for a half-year period indicates this is an Interim / Quarterly Report rather than a brief announcement or a full annual report. The document length (15,000 characters) and content depth confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-02-28 English
Mesoblast 2024 Half Year Financial Results Webcast 1
Report Publication Announcement Classification · 95% confidence The document is a short announcement about an upcoming webcast to discuss financial results for the six months ended December 31, 2023. It provides details on the webcast timing, access link, and company background but does not contain actual financial statements or substantive financial data. The document length is 2861 characters, which is relatively short and consistent with an announcement rather than a full report. It states that the webcast will discuss financial results but does not present the results themselves. Therefore, this document is best classified as a Report Publication Announcement (RPA), as it announces the timing and availability of a financial results webcast rather than providing the financial report itself.
2024-02-25 English
6-K
Regulatory Filings
2024-02-20 English
FDA Grants Orphan Drug Designation for Revascor 3 pages 188.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the FDA has granted Orphan-Drug Designation and Rare Pediatric Disease Designation for Mesoblast's product Revascor. It discusses clinical trial results, regulatory designations, and future plans for approval discussions with the FDA. There are no financial statements, earnings data, or detailed financial analysis present. The content is primarily a regulatory and product development update rather than a financial report or filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. It is an announcement about regulatory status and clinical trial outcomes, which is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2024-02-14 English
6-K
Regulatory Filings
2024-02-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 516.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023' and provides detailed operational and financial information for the quarter ending December 31, 2023. It includes substantive financial data such as cash balances, capital raising details, net operating cash spend, revenue from royalties, and cost containment strategies. The document also discusses clinical trial progress and regulatory interactions, but the primary focus is on quarterly operational and financial performance. The length of the document (15,000 characters) and the presence of detailed financial figures and analysis confirm it is a comprehensive quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-01-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.